A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis

NCT05139680 · clinicaltrials.gov ↗

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype

Interventions

DRUG: tafamidis

Sponsor

Pfizer